In the wake of a recent safety scare in a confirmatory trial of its antibody-drug conjugate Zynlonta, ADC Therapeutics is tightening its belt in an effort to get the most out of its cancer med. On ...

A comprehensive MATLAB toolbox for ADC (Analog-to-Digital Converter) testing, characterization, and debugging. This toolbox provides advanced functions for spectral analysis, calibration, linearity ...

In addition to a high rate of deaths, ADC Therapeutics’ Zynlonta plus rituximab showed no overall survival benefit in patients with diffuse large B cell lymphoma, casting doubt on its value as a ...

Researchers from Hangzhou DAC Biotechnology Co. Ltd. reported preclinical efficacy data for DXC-016, a next-generation, subcutaneously administered, dual-payload c-Met-targeting antibody-drug ...

Pivotal ADC approval trials in gynecologic cancers disproportionately enrolled White, younger, fitter, less-pretreated patients, limiting generalizability to routine oncology practice. Real-world ...

The internet’s favorite encyclopedia has officially banned its 260,000 human editors from using artificial intelligence to write articles — a major crackdown as so-called “AI slop” floods the web. The ...

Wikipedia recently published guidelines prohibiting the use of AI to generate or rewrite articles, except for two exceptions related to editing and translations. The guidelines acknowledges that ...

Wikipedia has banned contributors from using artificial intelligence tools to create content for its platform through a recent policy update. The recently announced new guidelines reflect increasing ...

A fresh rift has emerged in the African Democratic Congress (ADC) as the Nafi’u Bala Gombe-led Board of Trustees (BoT) and the party’s National Working Committee (NWC) on Sunday cautioned Bolaji ...

Antibody–drug conjugates (ADCs) are biomolecules — usually monoclonal antibodies (mAbs) — that are bound to a small drug molecule through a chemical linker. ADCs are targeted therapies; the mAb ...

Early relapse after curative-intent chemoimmunotherapy, especially with residual disease, concentrates within 6–12 months and creates a high-need population with limited therapies and frequent ...